{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:58:25Z","timestamp":1789347505275,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejca.2025.115703","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T22:29:01Z","timestamp":1754778541000},"page":"115703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-0191","authenticated-orcid":false,"given":"Christian","family":"Menzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-6353","authenticated-orcid":false,"given":"Susanne","family":"Dugas-Breit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-0788","authenticated-orcid":false,"given":"Martin","family":"Dugas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Reijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-8098","authenticated-orcid":false,"given":"Max","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-5430","authenticated-orcid":false,"given":"Karijn P.M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-3521","authenticated-orcid":false,"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-773X","authenticated-orcid":false,"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-9094","authenticated-orcid":false,"given":"Frank","family":"Meiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-9706","authenticated-orcid":false,"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2820","authenticated-orcid":false,"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Martin","family":"Thoms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Haalck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1810-0267","authenticated-orcid":false,"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0446-1907","authenticated-orcid":false,"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-2770","authenticated-orcid":false,"given":"Thomas","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Stevense-den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-114X","authenticated-orcid":false,"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Herbschleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115703_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (Columbus): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115703_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115703_bib3","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115703_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/onco.13795","article-title":"Efficacy and safety of trametinib in non-V600 BRAF mutant melanoma: a phase II study","volume":"26","author":"Nebhan","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2025.115703_bib5","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted therapy in advanced melanoma with rare BRAF mutations","volume":"37","author":"Menzer","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115703_bib6","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2025.115703_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3089","article-title":"Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: a systematic scoping review and meta-analysis","volume":"39","author":"Dankner","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115703_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.pathol.2018.08.004","article-title":"Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases","author":"Leichsenring","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.ejca.2025.115703_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2025.115703_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2025.115703_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/1078-0432.CCR-18-2062","article-title":"Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer","volume":"25","author":"Dagogo-Jack","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115703_bib12","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115703_bib13","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2025.115703_bib14","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115703_bib15","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115703_bib16","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/1078-0432.CCR-18-1680","article-title":"Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma","volume":"25","author":"Pires da Silva","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115703_bib17","article-title":"Non-V600E\/K BRAF mutations in metastatic melanoma: molecular description, frequency, and effectiveness of targeted therapy in a large national cohort","volume":"6","author":"Girod","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115703_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.115703_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115703_bib20","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1158\/1078-0432.CCR-17-3384","article-title":"Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanomas","volume":"24","author":"Dankner","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115703_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115703_bib22","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115703_bib23","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: results from the expansion arm of a phase Ib, open-Label study","volume":"41","author":"de Braud","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492500485X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492500485X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:43:21Z","timestamp":1779702201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492500485X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"alternative-id":["S095980492500485X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115703","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115703"}}